The rejuvenated pressurised metered dose inhaler

Bibliography

• ANDERSON PJ: History of aerosol therapy; liquid nebulization to MDIs and DPIs. Respir. Care (2005) 50:1139-1150.
   PubMedGoogle Scholar
• SCIARRA JJ, STOLLER L: The science and technology of aerosol packaging. John Wiley, New York (1974).
   Google Scholar
• THIEL CG: From Susie’s question to CFC free: an inventor’s perspective on forty years of MDI development and regulation. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, Buffalo Grove (1996):115-123.
   Google Scholar
• FINK JB: Metered dose inhalers, dry powder inhalers and transitions. Respir. Care (2000) 45:623-635.
   PubMedGoogle Scholar
• BROWN BAS: Dispelling the myths of MDIs. Drug Delivery Technology (2002) 2:1-7.
   Google Scholar
• TANSEY IP: The challenges in the development of metered-dose inhalation aerosols using ozone-friendly propellants. Proceedings of the First European Pharm. Tech. Conference, Dusseldorf (1993):182-187.
   Google Scholar
• SMITH IJ, PARRY-BILLINGS M: The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. (2003) 16:79-95.
   PubMed Web of Science ®Google Scholar
• DALBY R, SPALLEK M, VOSHAAR T: A review of the development of Respimat soft mist inhaler. Int. J. Pharm. (2004) 283:1-9.
   PubMed Web of Science ®Google Scholar
• NOAKES T: Medical aerosol propellants. J. Fluorine Chem. (2002) 118:35-45.
   Web of Science ®Google Scholar
• SANDERS PA: Principles of aerosol technology. Van Nostrand Reinhold, New York (1970).
   Google Scholar
• HALLWORTH GW: The formulation and evaluation of pressurised metered dose inhalers. In: Drug delivery to the respiratory tract. Ganderton D, Jones T (Eds). Ellis Horwood, Chichester (1987):87-118.
   Google Scholar
• NEWMAN SP: Principles of metered-dose inhaler design. Respir. Care (2005) 50:1177-1190.
   PubMedGoogle Scholar
• BYRON PR: Aerosol formulation, generation and delivery using metered systems. In: Respiratory Drug Delivery. Byron PR (Ed.). CRC Press, Boca Raton (1991):167-205.
   Google Scholar
• BELL JH, BROWN K, GLASBY J: Variation in delivery of isoprenaline from various pressurized inhalers. J. Pharm. Pharmacol. (1973) 25(Suppl.):32P-36P.
   PubMed Web of Science ®Google Scholar
• CLARK AR: MDIs: physics of aerosol formation. J. Aerosol Med. (1996) 9(Suppl. 1):S19-S26.
   Google Scholar
• DUNBAR CA, WATKINS AP, MILLER JF: Theoretical investigation of the spray from a pressurized metered-dose inhaler. Atomisation and Sprays (1997) 7:417-436.
   Web of Science ®Google Scholar
• VERSTEEG HK, HARGRAVE GK: Fundamentals and resilience of the original MDI actuator design. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):91-100.
   Google Scholar
• RANCE RW: Studies of the factors controlling the action of hair sprays. J. Soc. Cosmet. Chem. (1974) 25:545-561.
   Web of Science ®Google Scholar
• GABRIO BJ, STEIN SW, VELASQUEZ DJ: A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm. (1999) 186:3-12.
   PubMed Web of Science ®Google Scholar
• DOLOVICH M, RUFFIN RE, ROBERTS R, NEWHOUSE MT: Optimal delivery of aerosols from metered dose inhalers. Chest (1981) 80(Suppl.):911-915.
   PubMed Web of Science ®Google Scholar
• SHORT MD, SINGH CA, FEW JD, STUDDY PT, HEAF PJD, SPIRO SG: The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent. Chest (1981) 80(Suppl.):918-921.
   PubMed Web of Science ®Google Scholar
• NEWMAN SP, PAVIA D, GARLAND N, CLARKE SW: Effects of various inhalation modes on the deposition of radioactive pressurised aerosols. Eur. J. Respir. Dis. (1982) 63(Suppl. 119):57-65.
   Google Scholar
• HINDLE M, NEWTON DAG, CHRYSTYN H: Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax (1993) 48:607-610.
   PubMed Web of Science ®Google Scholar
• NEWMAN SP: Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Ther. Drug Carrier Syst. (1993) 10:65-109.
   PubMed Web of Science ®Google Scholar
• NEWMAN SP, WEISZ AWB, TALAEE N, CLARKE SW: Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax (1991) 46:712-716.
   PubMed Web of Science ®Google Scholar
• MOLINA MJ, ROWLANDS FS: Stratospheric sink for chlorofluoromethanes: chlorine atomcatalysed destruction of ozone. Nature (1974) 249:1810-1812.
   Web of Science ®Google Scholar
• PARTRIDGE MR, WOODCOCK AA, SHEFFER AL, WANNER A, RUBINFELD A: Chlorofluorocarbon-free inhalers: are we ready for the change? Eur. Respir. J. (1998) 11:1006-1008.
   PubMed Web of Science ®Google Scholar
• PARTRIDGE MR, WOODCOCK AA: Propellants. In: Drug Delivery to the Lung. Bisgaard H, O’Callaghan C, Smaldone GC (Eds) Marcel Dekker, New York (2002):371-388.
   Google Scholar
• LAWFORD P, MCKENZIE D: Pressurised aerosol inhaler technique: how important are inhalation from residual volume, inspiratory flow rate and time interval between puffs? Br. J. Dis. Chest (1983) 77:276-281.
   PubMedGoogle Scholar
• NEWMAN SP, PAVIA D, CLARKE SW: How should a pressurised β-adrenergic bronchodilator be inhaled? Eur. J. Respir. Dis. (1981) 62:3-20.
   PubMedGoogle Scholar
• RILEY DJ, LIU RT, EDELMAN NH: Enhanced responses to aerosolised bronchodilator therapy in asthma using respiratory maneuvers. Chest (1979) 76:501-507.
   PubMed Web of Science ®Google Scholar
• CROMPTON GK: Problems patients have using pressurised aerosol inhalers. Eur. J. Respir. Dis. (1982) 63(Suppl. 119):57-65.
   Google Scholar
• MOLIMARD M, RAHERISON C, LIGNOT S, DEPONT F, ABOUELFATH A, MOORE N: Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. (2003) 16:249-254.
   PubMedGoogle Scholar
• LINDGREN S, BAKE B, LARSSON S: Clinical consequences of inadequate inhalation technique in asthma therapy. Eur. J. Respir. Dis. (1987) 70:93-98.
   PubMedGoogle Scholar
• GIRAUD V, ROCHE N: Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. (2002) 19:246-251.
   PubMed Web of Science ®Google Scholar
• BELL JH, HARTLEY PS, COX JSG: Dry powder aerosols I: a new powder inhalation device. J. Pharm. Sci. (1971) 10:1559-1564.
   Google Scholar
• HALLWORTH GW: An improved design of powder inhaler. Br. J. Clin. Pharmacol. (1977) 4:689-690.
   Web of Science ®Google Scholar
• WETTERLIN K: Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res. (1988) 5:506-508.
   PubMed Web of Science ®Google Scholar
• ASHURST I, MALTON A, PRIME D, SUMBY B: Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today (2000) 3:246-256.
   PubMedGoogle Scholar
• BRINDLEY A, SUMBY BS, SMITH IJ, HAYWOOD PA, GRANT AC: Design, manufacture and dose consistency of the Serevent Diskus Inhaler. Pharm. Tech. Eur. (1995) 9:14-22.
   Google Scholar
• LABIRIS NR, DOLOVICH MB: Pulmonary drug delivery. Part 1: physiological factors affecting therapeutic effectiveness of aerosolised medications. Br. J. Clin. Pharmacol. (2003) 56:588-599.
   PubMed Web of Science ®Google Scholar
• MORÉN F: Aerosol dosage forms and formulations. In: Aerosols in Medicine: principles, diagnosis and therapy. Morén F, Dolovich MB, Newhouse MT, Newman SP (Eds). Elsevier, Amsterdam (1993):321-350.
   Google Scholar
• PEART J, CLARKE MJ: New developments in dry powder inhaler technology. Am. Pharm. Rev. (2001) October:27-45.
   Web of Science ®Google Scholar
• LABIRIS NR, DOLOVICH MB: Pulmonary drug delivery. Part 2: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolised medications. Br. J. Clin. Pharmacol. (2003) 56:600-612.
   PubMed Web of Science ®Google Scholar
• ATKINS PJ: Dry powder inhalers: an overview. Respir. Care (2005) 50:1304-1312.
   PubMedGoogle Scholar
• TOBYN M, STANIFORTH JN, MORTON D, HARMER Q, NEWTON ME: Active and intelligent inhaler device development. Int. J. Pharm. (2004) 277:31-37.
   PubMedGoogle Scholar
• FINK JB, RUBIN BK: Problems with inhaler use: a call for improved clinician and patient education. Respir. Care (2005) 50:1360-1375.
   PubMedGoogle Scholar
• PRICE D: The way forward: dry powder inhalers should only be switched with physician agreement and patient training. Int. J. Clin. Pract. (2005) 59(Suppl. 59):36.
   Web of Science ®Google Scholar
• KELLING JS, STROHL KP, SMITH RL, ALTOSE MD: Physician knowledge in the use of canister nebulisers. Chest (1983) 83:612-614.
   PubMed Web of Science ®Google Scholar
• KESTEN S, ZIVE K, CHAPMAN KR: Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest (1993) 104:1737-1742.
   PubMed Web of Science ®Google Scholar
• RAU JL: Determinants of patient adherence to an aerosol regimen. Respir. Care (2005) 50:1346-1359.
   PubMedGoogle Scholar
• LEACH CL: The CFC to HFA transition and its impact on pulmonary drug development. Respir. Care (2005) 50:1201-1208.
   PubMedGoogle Scholar
• ATKINS PJ: Transition to HFA MDIs: how did we get there and where are we going? In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):83-90.
   Google Scholar
• SMITH IJ: The challenge of reformulation. J. Aerosol Med. (1995) 8:S19-S27.
   PubMedGoogle Scholar
• VERVAET C, BYRON PR: Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. (1999) 186:13-20.
   PubMed Web of Science ®Google Scholar
• CROWDER TM, LOUEY MD, SETHURAMAN VV, SMYTH HD, HICKEY AJ: 2001: An odyssey in inhaler formulation and design. Pharm. Tech. (2001) July:100-113.
   Google Scholar
• STEFELY JS, DUAN DC, MYRDAL PB, ROSS DL, SCHULTZ DW, LEACH CL: Design and utility of a novel class of biocompatible excipients for HFA-based MDIs. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, Raleigh (2000):83-90.
   Google Scholar
• STEFELY JS, BROWN B, HAMMERBECK DM, STEIN SW: Equipping the MDI for the 21st century by expanding its formulation options. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood, Raleigh (2002):207-214.
   Google Scholar
• CRIPPS A, RIEBE M, SCHULZE M, WOODHOUSE R: Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir. Med. (2000) 94(Suppl. B):S3-S9.
   PubMed Web of Science ®Google Scholar
• PEYRON ID, BRITTO IL, BENISSAN LB, TARDIEU BZ: Development and performance of a new hydrofluoroalkane (HFA-134a) based metered dose inhaler of salbutamol. Respir. Med. (2005) 99(Suppl. A):S20-S30.
   PubMed Web of Science ®Google Scholar
• LEACH CL, DAVIDSON PJ, HASSELQUIST BE, BOUDREAU RJ: Lung deposition of hydrofluroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest (2002) 122:510-516.
   PubMed Web of Science ®Google Scholar
• GANDERTON D, LEWIS D, DAVIES R, MEAKIN B, BRAMBILLA G, CHURCH T: Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir. Med. (2002) 96(Suppl. D):S3-S8.
   PubMed Web of Science ®Google Scholar
• SMYTH HDC: The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Advanced Drug Delivery Revs. (2003) 55:807-828.
   PubMed Web of Science ®Google Scholar
• SMYTH H, BRACE G, BARBOUR T, GALLION J, GROVE J, HICKEY AJ: Spray pattern analysis for metered dose inhalers: effect of actuator design. Pharm. Res. (2006) 23:1591-1596.
   PubMed Web of Science ®Google Scholar
• LEWIS DA, GANDERTON D, MEAKIN BJ, BRAMBILLA G: Theory and practice with solution systems. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2004):109-115.
   Google Scholar
• WOODCOCK A, ACERBI D, POLI G: Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir. Med. (2002) 96(Suppl. D):S9-S15.
   PubMed Web of Science ®Google Scholar
• LEWIS DA, MEAKIN BJ, BRAMBILLA G: New actuators versus old: reasons and results for actuator modifications for HFA solution MDIs. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):101-110.
   Google Scholar
• POLLI GP, GRIM WM, BACHER FA, YUNKER MH: Influence of formulation on aerosol particle size. J. Pharm. Sci. (1969) 58:484-486.
   PubMed Web of Science ®Google Scholar
• FOOD AND DRUG ADMINISTRATION: Chlorofluorocarbon propellants in self-propelled containers; addition to list of essential uses. Federal Register (1993) 58:6086-6088.
   Google Scholar
• COLTHORPE P: Industry experiences of the HFA transition. Drug Delivery Systems and Sciences (2003) 3:41-43.
   Google Scholar
• HOCHRAINER D, HÖLZ H, KREHER C, SCAFFIDI L, SPALLEK M, WACHTEL H: Comparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhaler. J. Aerosol Med. (2005) 18:273-282.
   PubMedGoogle Scholar
• ASHWORTH HL, WILSON CG, SIMS EE, WOTTON PK, HARDY JG: Delivery of propellant soluble drug from a metered dose inhaler. Thorax (1991) 46:245-247.
   PubMed Web of Science ®Google Scholar
• LEACH CL, DAVIDSON PJ, BOUDREAU RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. (1998) 12:1346-1353.
   PubMed Web of Science ®Google Scholar
• BUSSE WW, BRAZINSKY S, JACOBSON K et al.: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. (1999) 104:1215-1222.
   PubMed Web of Science ®Google Scholar
• DEROM E, PAUWELS RA: Pharmacokinetic and pharmacodynamic properties of inhaled beclomethasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin. Pharmacokinet. (2005) 44:815-836.
   PubMed Web of Science ®Google Scholar
• HARRISON LI: Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HFA metered dose inhaler formulations. J. Aerosol Med. (2002) 15:401-406.
   PubMedGoogle Scholar
• TASHKIN DP: HFA-BDP and its implications for the quiet zone. Respir. Med. (2000) 94(Suppl. D):S37-S39.
   PubMed Web of Science ®Google Scholar
• NEWMAN SP, PITCAIRN GR, KALIRAI CS et al.: Using gamma scintigraphy and single photon emission computed tomography to assess the pulmonary deposition of a new inhaled formulation of flunisolide. In: Drug Delivery to the Lungs XIII. The Aerosol Society, Portishead (2002):87-90.
   Google Scholar
• LEACH CT, BETHKE TD, BOUDREAU RJ et al.: Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a non-randmized study in healthy volunteers. J. Aerosol Med. (2006) 19:117-126.
   PubMedGoogle Scholar
• DEVADASON SG, HUANG T, WALKER S, TROEDSON R, LE SOUEF PN: Distribution of technetium-99m-labelled QVAR delivered using an Aurohaler device in children. Eur. Respir. J. (2003) 21:1007-1011.
   PubMed Web of Science ®Google Scholar
• BORGSTRÖM L OLSSON B, THORSSON L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J. Aerosol Med. (2006) 19:473-483.
   PubMedGoogle Scholar
• CYR TD, GRAHAM SJ, LI KYR, LOVERING EG: Low first-spray drug content in albuterol metered-dose inhalers. Pharm. Res. (1991) 8:658-660.
   PubMed Web of Science ®Google Scholar
• TOPLISS P, WARD D, SOUTHALL J, PUREWAL T: Pharmaceutical performance of a valve for metered dose inhalers designed to eliminate loss of prime. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):499-502.
   Google Scholar
• ROSS DL, GABRIO BJ: Advances in metered dose inhaler technology with the development of a chloroflurocarbon-free drug delivery system. J. Aerosol Med. (1999) 12:151-160.
   PubMedGoogle Scholar
• MARTIN AR, KWOK DY, FINLAY WH: Investigating the evaporation of metered-dose inhaler formulations in humid air: single droplet experiments. J. Aerosol Med. (2005) 18:218-224.
   PubMedGoogle Scholar
• NEWMAN SP: Inhaler treatment options in COPD. European Respiratory Review (2005) 14:102-108.
   Google Scholar
• HINDLE M, BYRON PR: Dose emissions from marketed dry powder inhalers. Int. J. Pharm. (1995) 116:169-177.
   Web of Science ®Google Scholar
• PRITCHARD JN: The future of metered-dose inhalers. Pharm. Tech. Eur. (2005) September:22-31.
   Google Scholar
• MEAKIN BJ, STROUD N: An evaluation of some metered dose aerosols using a twin stage impinger sampling device. J. Pharm. Pharmacol. (1983) 35(Suppl. 10):7P.
   PubMed Web of Science ®Google Scholar
• STEIN SW, FORSYTH BR, STEFELY JS, CHRISTENSEN JD, ALBAND TD, JINKS PA: Expanding the dosing range of metered dose inhalers through formulation and hardware optimisation. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2004):125-133.
   Google Scholar
• RUBIN BK, DUROTOYE L: How do patients determine that their metered-dose inhaler is empty? Chest (2004) 126:1134-1137.
   PubMed Web of Science ®Google Scholar
• SANDER N, FUSCO-WALKERT SJ, HARDER JM, CHIPPS BE. Dose counting and the use of pressurized metered-dose inhalers: running on empty. Ann. Allergy Asthma Immunol. (2006) 97:34-38.
   PubMed Web of Science ®Google Scholar
• CAIN WT, OPPENHEIMER JJ: The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann. Asthma Allergy Immunol. (2001) 87:417-419.
   PubMed Web of Science ®Google Scholar
• FOOD AND DRUG ADMINISTRATION: Guidance for industry: integration of dose counting mechanisms into MDI drug products (2003).
   Google Scholar
• EUROPOEAN AGENCY FOR EVALUATION OF MEDICINAL PRODUCTS: Final guideline on the quality of inhalation and nasal products (2005).
   Google Scholar
• BRADSHAW DRS: Developing dose counters: an appraisal based on regulator, pharma and user needs. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):121-131.
   Google Scholar
• HALLEY M: A review of the design and the development of GSK’s MDI dose counter. In: Drug Delivery to the Lungs 16. The Aerosol Society, Portishead (2005):77-80.
   Google Scholar
• SHETH K, WASSERNAN RL, LINCOURT WR, LOCANTORE NW, CARRANZA-ROSENZWEIG J, CRIM C: Fluticasone propionate/salmeterol hydrofluoroalkane via metered dose inhaler with integrated dose counter: performance and patient satisfaction. Int. J. Clin. Pract. (2006) 60:1218-1224.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN A, DEVINE T: Can patient adherence be improved with technology? In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):479-481.
   Google Scholar
• INGRAM S, NEWELL H, NINAN S, SOUTHWELL J, WARBY R: Design, development and analysis of an integrated pMDI dose counter. In: Drug Delivery to the Lungs 16. The Aerosol Society, Portishead (2005):148-151.
   Google Scholar
• MAHON G, PURKINS G: Selecting a dose counter for pMDIs. In: Respiratory Drug Delivery Europe. Dalby RN, Byron PR, Peart J, Suman JD (Eds), Davis Healthcare International, River Grove, Illinois (2005):165-167.
   Google Scholar
• BAUM EA: Design, development and testing of a new breath actuated inhaler. In: Inspiration: Developments in inhalation therapy. The Medicine Publishing Foundation, Oxford (1989):21-30.
   Google Scholar
• HARDY JG, JASUJA AK, FRIER M, PERKINS AC: A small volume spacer for use with a breath-operated pressurised metered dose inhaler. Int. J. Pharm. (1996) 142:129-133.
   Google Scholar
• FARR SJ, ROWE AM, RUBSAMEN R, TAYLOR G: Aerosol deposition in the human lung following administration from a microprocessor controlled metered dose inhaler. Thorax (1995) 60:639-644.
   Google Scholar
• BACON RJ, MCDERMOTT I, BELL J: A new breath operated actuator. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood, Raleigh (2002):403-406.
   Google Scholar
• MOHSEN N: pMDI aerosol momentum manipulation and biotargeted delivery. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood, Raleigh (2002):593-597.
   Google Scholar
• HUSEGAARD C: Consumer electronics to medical devices: a cross-industry perpective on technology development: breathing new life into next generation inhalers, a consumer-inspired next generation pMDI. In: Drug Delivery to the Lungs 17. The Aerosol Society, Portishead (2006):54-58.
   Google Scholar
• PRICE D, THOMAS M, MITCHELL G, NIZIOL C, FEATHERSTONE R: Improvement of asthma control with a breath-actuated pressurized metered dose inhaler: a prescribing claim study of 5556 patients using a traditional pressurized metered dose inhaler or a breath-actuated device. Respir. Med. (2003) 97:12-19.
   PubMed Web of Science ®Google Scholar
• BYRON PR: Platform selection for inhaled drugs: biological and regulatory merit of different approaches. In: Respiratory Drug Delivery Europe. Dalby RN, Byron PR, Peart J, Suman JD (Eds). Davis Healthcare International, River Grove, Illinois (2005):1-17.
   Google Scholar
• CHAPMAN KR, LOVE L, BRUBAKER H: A comparison of breath-actuated and conventional metered dose inhaler inhalation techniques in elderly subjects. Chest (1993) 104:1332-1337.
   PubMed Web of Science ®Google Scholar
• LENNEY J, INNES JA, CROMPTON GK: Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir. Med. (2000) 94:496-500.
   PubMed Web of Science ®Google Scholar
• PEDERSEN S, MORTENSEN S: Use of different inhalation devices in children. Lung (1990) 168(Suppl.):653-657.
   PubMed Web of Science ®Google Scholar
• PEDERSEN S: Choice of inhalation therapy in paediatrics. Eur. Respir. J. (1994) 18:85-88.
   Google Scholar
• CROMPTON GK: Breath-activated aerosol. Br. Med. J. (1971) 2:652-653.
   PubMedGoogle Scholar
• CROMPTON GK: The adult patient difficulties with inhalers. Lung (1990) 168(Suppl.):658-662.
   PubMed Web of Science ®Google Scholar
• LEACH CL, DAVIDSON PJ, HASSELQUIST BE, BOUDREAU RJ: Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J. Aerosol Med. (2005) 18:379-385.
   PubMedGoogle Scholar
• CHAPMAN KR, VOSHAAR TH, VIRCHOW JC. Inhaler choice in primary practice. European Respiratory Review (2005) 14:117-122.
   Google Scholar
• DALBY R, ZIEGLER L, SOMARAJU S, TSOUKLERIS M, TEETER J: The effect of time delays between inhaler actuation and onset of inhalation on the dose of albuterol exiting Optihaler, Aerochamber and Aerosol Cloud Enhancer spacers. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, Buffalo Grove (1996):324-326.
   Google Scholar
• HOWLETT D: Devices to assist patient co-ordination with pMDIs: a review. In: Drug Delivery to the Lungs IX. The Aerosol Society, Portishead (1998):184-187.
   Google Scholar
• ZHANG FL, GENOVA PA, TANGUAY JF et al.: The breath coordinated inhaler (BCI): a new pulmonary drug delivery device for pressurized metered dose inhalers. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, Raleigh (2000):323-326.
   Google Scholar
• O’CALLAGHAN C, WRIGHT P: The metered-dose inhaler. In: Drug Delivery to the Lung. Bisgaard H, O’Callaghan C, Smaldone GC (Eds). Marcel Dekker, New York (2002):337-370.
   Google Scholar
• NEWMAN SP, STEED KP, HOOPER G, JONES JI, UPCHURCH FC: Improved targeting of beclomethasone dipropionate (250 µg metered dose inhaler) to the lungs of asthmatics with the Spacehaler. Respir. Med. (1999) 93:424-431.
   PubMed Web of Science ®Google Scholar
• NEWNHAM DM, MCDEVITT DG, LIPWORTH BJ: Comparison of the extrapulmonary β-2 adrenoceptor responses and pharmacokinetics of salbutamol metered dose-inhaler and modified actuator device. Br. J. Clin. Pharmacol. (1993) 36:445-450.
   PubMed Web of Science ®Google Scholar
• NEWMAN SP, CLARKE SW: Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest (1993) 103:1442-1446.
   PubMed Web of Science ®Google Scholar
• NEWMAN SP, HIRST PH, BACON RE et al.: Pulmonary delivery of ergotamine tartrate using a new breath-actuated pressurized aerosol device, the aerosol drug delivery system. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, Raleigh (2000):471-473.
   Google Scholar
• KAKADE P, VERSTEEG H, DEATON D, HARGRAVE G: Design optimization of a novel MDI actuator. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):663-666.
   Google Scholar
• NEWMAN SP, NEWHOUSE MT: Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J. Aerosol Med. (1996) 9:55-70.
   PubMedGoogle Scholar
• TOBIN MJ, JENOURI G, DANTA I, KIM C, WATSON H, SACKNER MS: Response to bronchodilator drug administration by a new reservoir aerosol delivery system and a review of other auxiliary delivery systems. Am. Rev. Respir. Dis. (1982) 126:670-765.
   PubMed Web of Science ®Google Scholar
• SCHEUCH G, KOLB T, SOMMERER K, ROEDER S: In vitro evaluation of the novel spacer device Watchhaler and modeling of probable deposition in children. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):385-387.
   Google Scholar
• NEWMAN SP: Spacer devices for metered dose inhalers. Clin. Pharmacokinet. (2004) 43:349-360.
   PubMed Web of Science ®Google Scholar
• BISGAARD H, ANHOJ J, WILDHABER JH: Spacer devices. In: Drug Delivery to the Lung. Bisgaard H, O’Callaghan C, Smaldone GC (Eds). Marcel Dekker, New York (2002):389-420.
   Google Scholar
• GLEESON JGA, PRICE JF: Nebuhaler technique. Br. J. Dis. Chest (1988) 82:172-174.
   PubMedGoogle Scholar
• O’CALLAGHAN C, LYNCH J, CANT M, ROBERTSON C: Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation and avoiding multiple actuations of drug. Thorax (1993) 48:603-606.
   PubMed Web of Science ®Google Scholar
• BARRY PW, O’CALLAGHAN C: The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br. J. Clin. Pharmacol. (1995) 40:76-78.
   PubMed Web of Science ®Google Scholar
• MITCHELL J, MORTON R, SCHMIDT J, SNYDER S, DOYLE C, NAGEL M: Overcoming electrostatic charge retention in a new valved holding chamber (VHC): in vitro performance comparison with current devices. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2004):705-707.
   Google Scholar
• RUBIN BK, FINK JB: Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care (2005) 50:1191-1200.
   PubMedGoogle Scholar
• BRAND PLP, ROORDA RJ: Drug delivery in pediatric patients with asthma spacer devices versus nebulizers for β-2 agonists. Am. J. Drug Deliv. (2003) 1:61-70.
   Google Scholar
• GELLER DE: Comparing clinical features of the nebulizer, metered dose inhaler and dry powder inhaler. Respir. Care (2005) 50:1313-1322.
   PubMedGoogle Scholar
• ATKINS P: Discussion following NEWMAN SP: Principles of metered-dose inhaler design. Respir. Care (2005) 50:1177-1190.
   PubMedGoogle Scholar
• SMYTH HD: Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin. Drug Delivery (2005) 2:53-74.
   PubMedGoogle Scholar
• BOUNDY MG, LEITH D, KNOWLES MR: Dispersion and size distribution of amiloride by metered dose and dry powder inhalers. J. Aerosol Med. (1990) 3:233-241.
   Google Scholar
• MATHER LE, WOODHOUSE A, WARD ME, FARR SJ, RUBSAMEN RA, ELTHERINGTON LG: Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br. J. Clin. Pharmacol. (1998) 46:37-43.
   PubMed Web of Science ®Google Scholar
• ADJEI A, SUNDBERG D, MILLER J, CHUN A: Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. (1992) 9:244-249.
   PubMed Web of Science ®Google Scholar
• BROWN AR: Propellant-driven aerosols of proteins. Aerosol Science and Technology (1996) 24:45-56.
   Web of Science ®Google Scholar
• MARAJANI R, SHAIK MS, CHATTERJEE A, SINGH M: Evaluation of metered dose inhaler (MDI) formulations of ciclosporin. J. Pharm. Pharmacol (2007) 59:15-21.
   PubMed Web of Science ®Google Scholar
• BROWN AR, CHOWDHURY SL: Propellant-driven aerosols of DNA plasmids for gene expression in the respiratory tract. J. Aerosol Med. (1997) 10:129-146.
   Google Scholar
• BARNES PJ: The problem of cough and development of novel anti-tussives. Pulm. Pharmacol. Ther. (2006) Epub ahead of print.
   Google Scholar
• PRITCHARD JN, GENOVA P: Adapting the pMDI to deliver novel drugs: insulin and beyond. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):133-141.
   Google Scholar
• FRADLEY G: The pMDI – celebrating a golden history, welcoming a bright future. In: Drug Delivery to the Lungs 17. The Aerosol Society, Portishead (2006):38-41.
   Google Scholar
• CROMPTON GK, BARNES PJ, BROEDERS M et al.: The need to improve inhalation technique in Europe: a report from the aerosol drug management improvement team. Respir. Med. (2006) 27:1070-1071.
   Google Scholar
• COCHRANE MG, BALA MV, DOWNS KE, MAUSKOPF J, BEN-JOSEPH RH: Inhaled corticosteroids for asthma therapy: patient compliance, devices and inhalation technique. Chest (2000) 117:542-550.
   PubMed Web of Science ®Google Scholar
• DOLOVICH MB, AHRENS RC, HESS DR et al.: Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest (2005) 127:335-371.
   PubMed Web of Science ®Google Scholar
• LEWIS D, BRAMBILLA G, CHURCH T, MEAKIN B: BDP and formoterol association within combination HFA solution MDI. In: Respiratory Drug Delivery X. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International, River Grove, Illinois (2006):939-942.
   Google Scholar
• DHILLON S, KEATING GM: Beclomethasone dipropionate/formoterol: In an HFA-propelled pressurised metered dose inhaler. Drugs (2006) 66:1475-1483.
   PubMed Web of Science ®Google Scholar